Skip to main content
SpringerLink
Log in

Effect of Compound Recipe Gengniankang on senile sexual hormone and expression of estrogen receptor in bone of climacteric female rats

  • Experimental Work and Research
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Objective: To compare the therapeutic effect of Compound Recipe Gengniankang (GNK) with that of hormone replacement treatment (HRT) on climacteric female rats with osteoporosis, and to investigate the roles of estrogen and estrogen receptors in the mechanism of osteoporosis.Methods: Climacteric female rats with osteoporosis were chosen and divided into three groups (GNK group, HRT group and control group). Apoptosis of ovarian granulose cells was measured by terminal-deoxynucleotidyl transferae mediated nick end labeling (TUNEL) assay. Serum level of estrdiol (E2), follicle stimulating hormone (FSH), luteinizing hormone (LH) were determined by the method of radioimmunoassay (RIA). Reverse transcriptase polymerase chain reaction (RT-PCT) technology was used to evaluate the expression of estrogen receptor (ER) in bone. Bone mineral density (BMD) was measured by double energy X-ray absorption (DEXA).Results: In the climacteric rats, BMD, serum E2, ER mRNA expression in bone decreased remarkably, and serum FSH, LH and apoptosis of ovarian granulose cells increased obviously. After treating with GNK, all the indexes were reversed except serum E2. The increase of E2 was not significant.Conclusion: GNK is effective on climacteric osteoporosis female rats. Its role is performed not by increasing serum E2 but by enhancing ER in the bone and inhibiting apoptosis of ovarian granulose cells. GNK can deter further exhaustion of ovarian function.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Huber J. Phytoestrogens and SERMS, alternatives to classical hormone therapy? Ther Umsch 2000;57(10): 651–654.

    Article  PubMed  CAS  Google Scholar 

  2. Zhi HY, Li E. Effects of replenishing herbs and recipes on ER expression of bone tissue on ovariectomized rats osteoporosis. Chin J TCM Bas Med 2001;7 (4): 281–284.

    Google Scholar 

  3. Riggs BL, Hartmann LC. Selective estrogen-receptor modulators-mechanisms of action and application to clinical practice. N Engl J Med 2003;348(7): 618–629.

    Article  PubMed  CAS  Google Scholar 

  4. American College of Obstetricians and Gynecologists Committee on Practice Bulletins — Gynecology. ACOG Practice Bulletin. Selective estrogen receptor modulators. Int J Gynaecol Obstet 2002; 79(3): 289–298.

    Google Scholar 

  5. Tremollieres F, Lopes P. Specific estrogen receptor modulators (SERMs). Presse Med 2002;31 (28): 1323–1328.

    PubMed  Google Scholar 

  6. Littleton-Kearney MT, Ostrowski NL, Cox DA, et al. Selective estrogen receptor modulators: tissue actions and potential for CNS protection. CNS Drug Rev 2002;8(3): 309–330.

    Article  PubMed  CAS  Google Scholar 

  7. Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002;187(3): 521–527.

    Article  PubMed  CAS  Google Scholar 

  8. Sandberg K. HRT and SERMs: the good, the bad … and the lovely? Trends Endocrinol Metab 2002;13(8): 317–318.

    Article  PubMed  CAS  Google Scholar 

  9. Dowsett M, Bundred NJ, Decensi A, et al. Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients. Cancer Epidemiol Biomarkers Prev 2001;10(9): 961–966.

    PubMed  CAS  Google Scholar 

  10. Cummings SR, Duong T, Kenyon E, et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA 2002;287(2): 216–20.

    Article  PubMed  CAS  Google Scholar 

  11. Sirtori CR. Risks and benefits of soy phytoestrogens in cardiovascular diseases, cancer, climacteric symptoms and osteoporosis. Drug Saf 2001;24(9): 665–682.

    Article  PubMed  CAS  Google Scholar 

  12. Xie L, Guo ZQ, Yao GH. TCM syndrome differentiation analysis after osteoporosis of climacterium. Chin J Med Pharmaceut 1999;14(3): 35–39.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, The First Hospital, Shanxi Medical University, 030001, Taiyuan

    Wu Su-hui, Sun Jing-fen & Guo Shu-zhen

Authors
  1. Wu Su-hui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sun Jing-fen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Guo Shu-zhen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wu Su-hui.

Additional information

Supported by Shanxi Key Technology R&D Program (No. 20022074)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Su-hui, W., Jing-fen, S. & Shu-zhen, G. Effect of Compound Recipe Gengniankang on senile sexual hormone and expression of estrogen receptor in bone of climacteric female rats. Chin. J. Integr. Med. 11, 205–208 (2005). https://doi.org/10.1007/BF02836506

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02836506

Key Words

Search

Navigation